151 related articles for article (PubMed ID: 38134090)
1. Immunophenotypic p14 and p16 correlations with CDKN2A mutations in primary multiple and familial melanoma: An observational study.
Boşoteanu LA; Gheorghe E; Aşchie M; Cozaru GC; Deacu M; Orășanu CI; Boşoteanu M
Medicine (Baltimore); 2023 Dec; 102(51):e36756. PubMed ID: 38134090
[TBL] [Abstract][Full Text] [Related]
2. Novel and recurrent p14 mutations in Italian familial melanoma.
Binni F; Antigoni I; De Simone P; Majore S; Silipo V; Crisi A; Amantea A; Pacchiarini D; Castori M; De Bernardo C; Catricalà C; Grammatico P
Clin Genet; 2010 Jun; 77(6):581-6. PubMed ID: 20132244
[TBL] [Abstract][Full Text] [Related]
3. Loss of p16 expression and copy number changes of CDKN2A in a spectrum of spitzoid melanocytic lesions.
Harms PW; Hocker TL; Zhao L; Chan MP; Andea AA; Wang M; Harms KL; Wang ML; Carskadon S; Palanisamy N; Fullen DR
Hum Pathol; 2016 Dec; 58():152-160. PubMed ID: 27569296
[TBL] [Abstract][Full Text] [Related]
4. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
[TBL] [Abstract][Full Text] [Related]
5. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup.
Bruno W; Pastorino L; Ghiorzo P; Andreotti V; Martinuzzi C; Menin C; Elefanti L; Stagni C; Vecchiato A; Rodolfo M; Maurichi A; Manoukian S; De Giorgi V; Savarese I; Gensini F; Borgognoni L; Testori A; Spadola G; Mandalà M; Imberti G; Savoia P; Astrua C; Ronco AM; Farnetti A; Tibiletti MG; Lombardo M; Palmieri G; Ayala F; Ascierto P; Ghigliotti G; Muggianu M; Spagnolo F; Picasso V; Tanda ET; Queirolo P; Bianchi-Scarrà G
J Am Acad Dermatol; 2016 Feb; 74(2):325-32. PubMed ID: 26775776
[TBL] [Abstract][Full Text] [Related]
6. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.
Helsing P; Nymoen DA; Ariansen S; Steine SJ; Maehle L; Aamdal S; Langmark F; Loeb M; Akslen LA; Molven A; Andresen PA
Genes Chromosomes Cancer; 2008 Feb; 47(2):175-84. PubMed ID: 18023021
[TBL] [Abstract][Full Text] [Related]
7. CD8-Lymphocytic Phenotype Significance in Primary Multiple and Familial Melanoma with Various CDKN2A Mutational Status.
Boşoteanu LA; Gheorghe E; Aşchie M; Cozaru GC; Deacu M; Bălțătescu GI; Orășanu CI; Boşoteanu M
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138255
[No Abstract] [Full Text] [Related]
8. Loss of p16
Aesif SW; Aubry MC; Yi ES; Kloft-Nelson SM; Jenkins SM; Spears GM; Greipp PT; Sukov WR; Roden AC
J Thorac Oncol; 2017 May; 12(5):860-871. PubMed ID: 28179162
[TBL] [Abstract][Full Text] [Related]
9. A Combination of MTAP and p16 Immunohistochemistry Can Substitute for CDKN2A Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural Mesotheliomas.
Brcic L; Le Stang N; Gallob F; Pissaloux D; Sequeiros R; Paindavoine S; Pairon JC; Karanian M; Dacic S; Girard N; Churg A; Tirode F; Galateau-Salle F
Arch Pathol Lab Med; 2023 Mar; 147(3):313-322. PubMed ID: 35738002
[TBL] [Abstract][Full Text] [Related]
10. P16-CD8-Ki67 Triple Algorithm for Prediction of CDKN2A Mutations in Patients with Multiple Primary and Familial Melanoma.
Nurla LA; Gheorghe E; Aşchie M; Cozaru GC; Orășanu CI; Boşoteanu M
Diagnostics (Basel); 2024 Apr; 14(8):. PubMed ID: 38667459
[TBL] [Abstract][Full Text] [Related]
11. CDKN2A mutations and MC1R variants in Italian patients with single or multiple primary melanoma.
Pastorino L; Bonelli L; Ghiorzo P; Queirolo P; Battistuzzi L; Balleari E; Nasti S; Gargiulo S; Gliori S; Savoia P; Abate Osella S; Bernengo MG; Bianchi Scarrà G
Pigment Cell Melanoma Res; 2008 Dec; 21(6):700-9. PubMed ID: 18983535
[TBL] [Abstract][Full Text] [Related]
12. Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
Aydogdu G; Özekinci S
Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10001-10007. PubMed ID: 37916370
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous aberrations of single CDKN2A network components and a high Rb phosphorylation status can differentiate subgroups of primary cutaneous B-cell lymphomas.
Kaune KM; Neumann C; Hallermann C; Haller F; Schön MP; Middel P
Exp Dermatol; 2011 Apr; 20(4):331-5. PubMed ID: 21410763
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas.
Dacic S; Kothmaier H; Land S; Shuai Y; Halbwedl I; Morbini P; Murer B; Comin C; Galateau-Salle F; Demirag F; Zeren H; Attanoos R; Gibbs A; Cagle P; Popper H
Virchows Arch; 2008 Dec; 453(6):627-35. PubMed ID: 18958493
[TBL] [Abstract][Full Text] [Related]
15. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.
Smeds J; Berggren P; Ma X; Xu Z; Hemminki K; Kumar R
Carcinogenesis; 2002 Apr; 23(4):645-55. PubMed ID: 11960918
[TBL] [Abstract][Full Text] [Related]
16. Frequent deletion and methylation in SH3GL2 and CDKN2A loci are associated with early- and late-onset breast carcinoma.
Sinha S; Chunder N; Mukherjee N; Alam N; Roy A; Roychoudhury S; Kumar Panda C
Ann Surg Oncol; 2008 Apr; 15(4):1070-80. PubMed ID: 18239974
[TBL] [Abstract][Full Text] [Related]
17. The Amount of Melanin Influences p16 Loss in Spitzoid Melanocytic Lesions: Correlation With CDKN2A Status by FISH and MLPA.
Martinez Ciarpaglini C; Gonzalez J; Sanchez B; Agusti J; Navarro L; Nieto G; Monteagudo C
Appl Immunohistochem Mol Morphol; 2019 Jul; 27(6):423-429. PubMed ID: 29489509
[TBL] [Abstract][Full Text] [Related]
18. Multiple neurofibromas as the presenting feature of familial atypical multiple malignant melanoma (FAMMM) syndrome.
Vanneste R; Smith E; Graham G
Am J Med Genet A; 2013 Jun; 161A(6):1425-31. PubMed ID: 23613284
[TBL] [Abstract][Full Text] [Related]
19. High-Grade Endometrial Stromal Sarcomas With YWHAE::NUTM2 Gene Fusion Exhibit Recurrent CDKN2A Alterations and Absence of p16 Staining is a Poor Prognostic Marker.
Kommoss FKF; Mar LM; Howitt BE; Hanley K; Turashvilli G; Buslei R; Irving JA; Dickson BC; Koelsche C; Sinn HP; Schirmacher P; von Deimling A; Chiang S; McCluggage WG; Croce S; Stewart CJR; Lee CH
Mod Pathol; 2023 Mar; 36(3):100044. PubMed ID: 36788095
[TBL] [Abstract][Full Text] [Related]
20. Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression.
Ming Z; Lim SY; Rizos H
Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33076392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
